Women with high co-pays prone to stop cancer drug

than $2,000 a year when the study was done. Neugut and his colleagues used claims data from MedCo Health Solutions to find out what role patient co-pay might play in whether or not they took their drugs for the recommended five years. Of more than 8,000...